INNOVIVA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INNOVIVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-09-30 was 1.05M shares.
- INNOVIVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-06-30 was -354.00K shares.
- INNOVIVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-03-31 was 433.00K shares.
- INNOVIVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-12-31 was 688.00K shares.
- INNOVIVA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2013 was 2.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2014-09-30 | 1.05M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | 1.81M shares derived: sum of 4 quarters · filed 2014-11-04 |
| 2014-06-30 | -354.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | |
| 2014-03-31 | 433.00K shares 10-Q · filed 2014-05-07 | |
| 2013-12-31 | 688.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | 2.00M shares 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |